Navigation Links
Phase Genomics Proximo Hi-C Technology Featured in Nature Genetics
Date:3/6/2017

Today, an article co-authored by founders of Phase Genomics was published in Nature Genetics, summarizing the assembly of the most contiguous de novo mammalian genome to-date. The ultra-long-range scaffolds in this goat genome were made possible by Phase Genomics’ revolutionary genome scaffolding technology now called Proximo™ Hi-C – the first commercial offering of in vivo Hi-C based genome assembly and the commercial successor to the Lachesis method described in the article. The study was spearheaded by a group of researchers from the USDA, NHGRI, and Virginia State University, together with Phase Genomics and other commercial entities.

“We are pleased to have the opportunity to share the results of this groundbreaking project with Nature Genetics readers,” said company CEO, Ivan Liachko. “This paper highlights a fundamental advancement in genome assembly and I'm thrilled to see the animal community gain such an amazing resource.”

The Proximo Hi-C scaffolding platform is the fastest and most affordable solution for end-to-end scaffolding of de novo genomes. Genomes assembled without this process are fragmented and often omit critical biological information.

For this project, Pacific Biosciences long-read shotgun sequencing, Illumina short reads, and BioNano Irys optical mapping were used to generate a draft assembly. The Proximo Hi-C process was then used in combination with custom analysis to create chromosome-level scaffolds.

“We saw similar results in our work with Phase Genomics on plants and look forward to publishing similar outcomes soon,” said Prof. Jeff Maughan, a plant researcher at Brigham-Young University. “The level of genome completeness and contiguity yielded by this technology has transformed how we view genome projects and has enabled us to ask new biological questions.”

Interested parties can learn more about Proximo Hi-C and other Phase Genomics services by visiting their website at http://www.phasegenomics.com.

Read the full story at http://www.prweb.com/releases/2017/03/prweb14121855.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. SELLAS Life Sciences Announces Updated Positive Phase 2 Data Reinforcing Meaningful Clinical Benefit of its WT1 Immunotherapeutic Anti-cancer Treatment in Multiple Myeloma Patients
2. OncoGenex Pharmaceuticals, Inc. Announces Phase 2 Apatorsen Data for Two Clinical Trials Presented at the American Society of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium
3. BERG Initiates Phase I/II Monotherapy Trial of BPM 31510-IV in Patients with Glioblastoma Multiforme (GBM)
4. VM BioPharma Announces Publication of Phase 1/2 Clinical Data of Novel Gene Therapy VM202 in Amyotrophic Lateral Sclerosis (ALS)
5. OncoSec to Present New Clinical Data from Phase 2 Combination Study at ASCO-SITC Clinical Immuno-Oncology Symposium and Corporate Updates at Two Investment Conferences in February
6. Sirnaomics Initiates a Clinical Phase IIa Study of Its Leading siRNA Therapeutic Candidate, STP705, for Treatment of Hypertrophic Scar
7. Envisia Therapeutics Releases Interim ENV515 (Travoprost XR) Phase 2 Data Demonstrating 11-Month Duration-of-Action After a Single Dose in Patients With Glaucoma
8. Roche selects Vivonoetics to provide advanced respiratory assessment for the FIREFISH Phase II multicenter clinical trial in infants with Spinal Muscular Atrophy Type 1.
9. Protagonist Therapeutics Initiates Phase 2b Study of Oral Drug Candidate PTG-100 in Ulcerative Colitis
10. Phase Genomics Announces Commercial Availability of Rapid End-to-End Genome Assembly Service
11. Symbios Announces National Science Foundation SBIR Phase IIB Award to Commercialize Plasma Oxidation Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... August 17, 2017 , ... ... market news outlet had provided a research update on Aytu Bioscience and cited ... product. , According to Soulstring, prescription rates for Natesto® have more than doubled ...
(Date:8/16/2017)... ... 16, 2017 , ... Tunnell Consulting announced today that four of ... Annual Meeting and Expo , to be held October 29 through November 1 in ... innovation to advance patient therapies.” , The ISPE Annual Meeting and Expo will feature ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... a different cell type. Many treatments for specific cancers, such as breast, prostate, ... targeted treatment is androgen deprivation therapy for advanced prostate cancer. , This ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... ... beneficial microbe delivery system, announced it has secured $2M in funding from an ... City Angels, Carmen Innovations, and SVG Thrive Fund. With this investment, 3Bar is ...
Breaking Biology Technology:
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
Breaking Biology News(10 mins):